Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis Publisher



Mortezaei A1 ; Emara M2 ; Habibi MA3 ; Yazdanian F4, 5 ; Mohammadzadeh I6 ; Dmytriw AA7, 8 ; Rahmani R9 ; Liebeskind DS10, 11
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medicine, Gonabad University of Medical Sciences, Iran
  2. 2. College of Medicine, University of Sharjah, United Arab Emirates
  3. 3. Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Science, Iran
  4. 4. Department of Neurosurgery, Beth Israel Deaconess Medical Center, United States
  5. 5. Department of Neurosurgery, Harvard Medical School, United States
  6. 6. Skull Base Research Center, Loghman-Hakim Hospital, Shahid Beheshti University of Medical Sciences, Iran
  7. 7. Neurovascular Centre, Departments of Medical Imaging & Neurosurgery, St. Michael’s Hospital, University of Toronto, Canada
  8. 8. Massachusetts General Hospital & Brigham and Women’s Hospital, Harvard Medical School, United States
  9. 9. Department of Neurosurgery, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, United States
  10. 10. Neurovascular Imaging Research Core, University of California, United States
  11. 11. Comprehensive Stroke Center, Department of Neurology, David Geffen School of Medicine at the University of California, United States

Source: Neuroradiology Journal Published:2025


Abstract

Background: Edaravone dexborneol has been developed as a novel neuroprotective agent and showed a promising result in treatment of stroke. The current meta-analysis aimed to assess the feasibility and efficacy of the edaravone dexborneol in the treatment of stroke. Method: We performed a systematic review and meta-analysis of literature in four electronic databases. Binary outcomes were analyzed through the risks ratio (RR) and 95% confidence interval (CI), while the continuous outcomes were analyzed through the standardized mean difference (SMD) and 95% CI. Also, we did a subgroup analysis to show more feasibility and safety dimensions. Results: Five studies with a total of 2415 patients were included. There were 1119 patients in edaravone dexborneol group and 1216 patients in control group. The 90-mRS 0–1 (RR 1.17 [95% CI 1.09–1.25]; p < 0.0001) and 90-day mRS 0–2 (RR 1.12 [95% CI 1.07–1.18]; p < 0.0001) were statistically significant higher in intervention group compared with control group. There was no significant difference between intervention group and control group concerning 90-day mRS 0–3 (RR 1.03 [95% CI 0.99–1.06]; p = 0.07), 90-day mortality rate (RR 0.71 [95% CI 0.45–1.11]; p = 0.13), serious adverse events (RR 0.91 [95% CI 0.72–1.16]; p = 0.45), and NIHSS score ≤1 at days 14 (RR 0.96; p = 0.69), 30 (RR 1.08; p = 0.18), and 90 (RR 1.06; p = 0.15). No heterogeneity in treatment effect was seen in the analysis, and any potential discrepancies were addressed by sensitivity analysis. Conclusion: Edaravone dexborneol can be a favorable treatment option for patients with stroke. However, more randomized controlled trials are required to confirm our findings. © The Author(s) 2025.
Related Docs
1. Potential of Edaravone Dexborneol in the Treatment of Cerebral Ischemia: Focus on Cell Death-Related Signaling Pathways, Molecular Biology Reports (2024)
2. Reevaluating the Role of Heparin During Mechanical Thrombectomy for Acute Ischemic Stroke: Increased Risks Without Functional Benefit, Clinical Neurology and Neurosurgery (2024)
3. The 100 Highest-Cited Original Articles in Large Vessel Occlusions: A Bibliometric Analysis, Neuroradiology Journal (2025)
Experts (# of related papers)
Fatemeh Nabavizadeh Rafsanjani (1)